Furthermore, GLP-1 drugs had a favorable safety profile versus aspirin, particularly with respect to bleeding events, said ...

In a strategic move that could protect its obesity pipeline from future patent litigation, Roche is paying $100 million to ...

Among adolescents with asthma and overweight or obesity, the relative risk for acute asthma exacerbations was significantly reduced with GLP-1 receptor agonist use vs. nonpharmacological weight ...

Lower risk for foot disease driven by lower risk for neuropathy for new users of SGLT-2 inhibitors versus GLP-1 receptor agonists ...

Use of liraglutide or semaglutide therapy does not increase risk for thyroid cancer among patients with type 2 diabetes or obesity.

Meanwhile, in attempts to address long-standing thyroid cancer concerns, a research team conducted a 350,000-person analysis ...

MDR-001 progressed from program discovery to Phase III in just 4.5 years, much faster than traditional development ...

The sustainability of weight-loss drugs is under scrutiny as new research shows that people who stop taking glucagon-like ...

Odds of vertebral compression fractures or surgical intervention were significantly lower among GLP-1 RA users.

- Utilizing Ascletis' Peptide Oral Transport ENhancement Technology (POTENT), ASC37 oral tablets achieved average absolute oral bioavailability of 4.2%, approximately 9-, 30-, and 60-fold higher than ...

This year’s top health trend will be the expanded use of GLP-1 receptor agonists to treat chronic disease, according to experts surveyed by the editors of U.S. News and World Report. Tied for second ...

Some dietary supplements may help naturally boost GLP-1, but more research is needed to better understand their potential ...